<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK26472" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK26472/" /><meta name="ncbi_pagename" content="PINK1 Type of Young-Onset Parkinson Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>PINK1 Type of Young-Onset Parkinson Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="PINK1 Type of Young-Onset Parkinson Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/05/24" /><meta name="citation_author" content="Susanne A Schneider" /><meta name="citation_author" content="Christine Klein" /><meta name="citation_pmid" content="20301792" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK26472/" /><meta name="citation_keywords" content="Serine/threonine-protein kinase PINK1, mitochondrial" /><meta name="citation_keywords" content="PINK1" /><meta name="citation_keywords" content="PINK1 Type of Young-Onset Parkinson Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="PINK1 Type of Young-Onset Parkinson Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Susanne A Schneider" /><meta name="DC.Contributor" content="Christine Klein" /><meta name="DC.Date" content="2018/05/24" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK26472/" /><meta name="description" content="PINK1 type of young-onset Parkinson disease is characterized by early onset (mean age 33 years) of tremor, bradykinesia, and rigidity that are often indistinguishable from other causes of Parkinson disease. Lower-limb dystonia may be a presenting sign. Postural instability, hyperreflexia, abnormal behavior, and psychiatric manifestations have been described. The disease is usually slowly progressive. Individuals have a marked and sustained response to oral administration of levodopa (L-dopa), frequently associated with L-dopa-induced fluctuations and dyskinesias." /><meta name="og:title" content="PINK1 Type of Young-Onset Parkinson Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="PINK1 type of young-onset Parkinson disease is characterized by early onset (mean age 33 years) of tremor, bradykinesia, and rigidity that are often indistinguishable from other causes of Parkinson disease. Lower-limb dystonia may be a presenting sign. Postural instability, hyperreflexia, abnormal behavior, and psychiatric manifestations have been described. The disease is usually slowly progressive. Individuals have a marked and sustained response to oral administration of levodopa (L-dopa), frequently associated with L-dopa-induced fluctuations and dyskinesias." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK26472/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pink1-pd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK26472/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CE3E7E041196100000000038F0151.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK26472_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK26472_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pik3ca-overgrowth/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/inad/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK26472_"><span class="title" itemprop="name"><i>PINK1</i> Type of Young-Onset Parkinson Disease</span></h1><p class="contrib-group"><span itemprop="author">Susanne A Schneider</span>, MD, PhD and <span itemprop="author">Christine Klein</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK26472_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK26472_ai__"><div class="contrib half_rhythm"><span itemprop="author">Susanne A Schneider</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Ludwig Maximilian University<br />Munich, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.nehcneum-inu.dem@redienhcs.ennasus" class="oemail">ed.nehcneum-inu.dem@redienhcs.ennasus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christine Klein</span>, MD<div class="affiliation small">Institute of Neurogenetics<br />Department of Neurology<br />University of L&#x000fc;beck<br />L&#x000fc;beck, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.kcebeul-inu.oruen@nielk.enitsirhc" class="oemail">ed.kcebeul-inu.oruen@nielk.enitsirhc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 16, 2010</span>; Last Update: <span itemprop="dateModified">May 24, 2018</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pink1-pd.Summary" itemprop="description"><h2 id="_pink1-pd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>PINK1</i> type of young-onset Parkinson disease is characterized by early onset (mean age 33 years) of tremor, bradykinesia, and rigidity that are often indistinguishable from other causes of Parkinson disease. Lower-limb dystonia may be a presenting sign. Postural instability, hyperreflexia, abnormal behavior, and psychiatric manifestations have been described. The disease is usually slowly progressive. Individuals have a marked and sustained response to oral administration of levodopa (L-dopa), frequently associated with L-dopa-induced fluctuations and dyskinesias.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>PINK1</i> type of young-onset Parkinson disease is suspected in individuals with early-onset parkinsonism (age &#x0003c;40 years), particularly if <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance is suggested by the family history. The diagnosis of <i>PINK1</i> type of young-onset Parkinson disease is established by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>PINK1</i> pathogenic variants on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> This disorder usually responds well to L-dopa and other dopaminergic therapies. L-dopa-induced dyskinesias can be reduced by adjusting dopaminergic therapies and by adding antidyskinetic agents. Motor fluctuations can be ameliorated by dose fractionation and by adding COMT inhibitors. As in individuals with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease, deep brain stimulation should be considered in more advanced cases.</p><p><i>Prevention of secondary complications:</i> L-dopa dosage should not exceed the level required for satisfactory clinical response. If not contraindicated, dopamine agonists should be employed to possibly delay the onset of motor fluctuations, as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals often require several decades of treatment.</p><p><i>Surveillance:</i> Neurologic follow up including assessment of treatment effectiveness every three to 12 months.</p><p><i>Agents/circumstances to avoid:</i> Neuroleptic treatment may exacerbate parkinsonism.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>PINK1</i> type of young-onset Parkinson disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if both pathogenic variants have been identified in an affected family member.</p></div></div><div id="pink1-pd.Diagnosis"><h2 id="_pink1-pd_Diagnosis_">Diagnosis</h2><p>Updated guidelines on the molecular diagnosis of Parkinson disease were provided in a joint effort by the European Federation of Neurological Societies (EFNS), the European Section of the International Parkinson and Movement Disorders Society (MDS-ES), and the European Neurological Society (ENS) [<a class="bk_pop" href="#pink1-pd.REF.berardelli.2013.16">Berardelli et al 2013</a>]. Some national societies (e.g., the German Society of Neurology) have also published guidelines on the molecular diagnosis of Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.finckh.2016">Finckh &#x00026; Rie&#x000df; 2016</a>].</p><div id="pink1-pd.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>PINK1</i> type of young-onset Parkinson disease <b>should be suspected</b> in individuals with the following findings:</p><ul><li class="half_rhythm"><div>Early onset (reported in 62%) (late onset in 22%, juvenile onset in 15%)</div></li><li class="half_rhythm"><div>Bradykinesia (77%)</div></li><li class="half_rhythm"><div>Rigidity (62%)</div></li><li class="half_rhythm"><div>Dyskinesia (39%)</div></li><li class="half_rhythm"><div>Motor fluctuations (34%)</div></li><li class="half_rhythm"><div>Dystonia reported in 21% (often of the lower limbs), either as a presenting sign or occurring during disease progression. Notably, dystonia was absent in 35%, and no details given in 50% of individuals.</div></li><li class="half_rhythm"><div>Cognitive decline (14%)</div></li><li class="half_rhythm"><div>Psychotic symptoms (9%)</div></li><li class="half_rhythm"><div>Good response to levodopa (L-dopa) treatment (in 99% of individuals with a reported ledopa response)</div></li><li class="half_rhythm"><div>A family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p>Note: (1) This information is based on 139 reported individuals (from <a href="http://www.mdsgene.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">mdsgene.org</a>; May 3, 2018). Notably, clinical information was often incomplete (e.g., information on olfactory function was available for 16 of the 139 individuals only). (2) <i>PINK1</i> type of young-onset Parkinson disease is often clinically indistinguishable from Parkinson disease caused by pathogenic variants in <i>PRKN</i> or <i>PARK7</i> or <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease.</p></div><div id="pink1-pd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>PINK1</i> type of young-onset Parkinson disease <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PINK1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK26472/table/pink1-pd.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figpink1pdTmoleculargenetictestinguse" rid-ob="figobpink1pdTmoleculargenetictestinguse">Table 1</a>). Molecular genetic testing for pathogenic variants in <i>PINK1</i> and other genes in which pathogenic variants cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Parkinson disease (e.g., <i>PRKN</i>, <i>PARK7</i>) is recommended in families in which autosomal recessive inheritance is suspected (<a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib pairs) or in <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases with early onset (age &#x0003c;40 years) [<a class="bk_pop" href="#pink1-pd.REF.berardelli.2013.16">Berardelli et al 2013</a>]. Identification of a single <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is only suggestive (i.e., not diagnostic) of <i>PINK1</i> type of young-onset Parkinson disease.</p><p>Molecular genetic testing approaches can include a combination of <b>a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Individuals with the distinctive findings described in <a href="#pink1-pd.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using <b>a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> (see <a href="#pink1-pd.Option_1">Option 1</a>), whereas those in whom the diagnosis of <i>PINK1</i> type of young-onset Parkinson disease has not been considered are more likely to be diagnosed using genomic testing (see <a href="#pink1-pd.Option_2">Option 2</a>).</p><div id="pink1-pd.Option_1"><h4>Option 1</h4><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PINK1</i>, <i>PRKN</i>, <i>PARK7</i>, and other genes of interest (see <a href="#pink1-pd.Differential_Diagnosis">Differential Diagnosis</a>) should be considered first. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="pink1-pd.Option_2"><h4>Option 2</h4><p>When the diagnosis of <i>PINK1</i> type of young-onset Parkinson disease is not considered because an individual has atypical phenotypic features, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p></div><div id="pink1-pd.Option_3_not_often_recommended"><h4>Option 3 (not often recommended)</h4><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>PINK1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>PINK1</i> followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><div id="pink1-pd.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>PINK1</i> Type of Young-Onset Parkinson Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26472/table/pink1-pd.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pink1-pd.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PINK1</i></td><td headers="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_pink1-pd.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;10%&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pink1-pd.TF.1.1"><p class="no_margin">See <a href="/books/NBK26472/#pink1-pd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pink1-pd.TF.1.2"><p class="no_margin">See <a href="#pink1-pd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="pink1-pd.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="pink1-pd.TF.1.4"><p class="no_margin">See <a href="#pink1-pd.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>.</p></div></dd><dt>5. </dt><dd><div id="pink1-pd.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div></div><div id="pink1-pd.Clinical_Characteristics"><h2 id="_pink1-pd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="pink1-pd.Clinical_Description"><h3>Clinical Description</h3><p>The following information is based on a systematic review of published reports including 139 individuals with <i>PINK1</i> type of young-onset Parkinson disease from 85 families (see <a href="http://www.mdsgene.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a> and references therein).</p><p>The majority of individuals (62%) have early onset, 22% have late onset, and 15% have juvenile onset (see <a href="http://www.mdsgene.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a>. Note: The age of onset was not specified in 10% of individuals). The mean age of onset is 32.6&#x000b1;12.1 years [<a class="bk_pop" href="#pink1-pd.REF.kasten.2010a.670">Kasten et al 2010a</a>]. Women and men are equally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>Symptoms are usually asymmetric (i.e., one side of the body is more affected than the other); in some individuals the symptoms at onset are symmetric. Bradykinesia and tremor are the most common presenting signs. Dystonia (often of the lower limbs) and hyperreflexia may also be present at onset or develop as the disease progresses [<a class="bk_pop" href="#pink1-pd.REF.bonifati.2005.87">Bonifati et al 2005</a>]. The disease is slowly progressive. Rigidity (93%) and postural instability (65%) occur with disease progression. Sleep benefit was reported for 12% of individuals (see <a href="http://www.mdsgene.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a>) [<a class="bk_pop" href="#pink1-pd.REF.kasten.2018.730">Kasten et al 2018</a>].</p><p>Nonmotor symptoms and sleep impairment are common in individuals with <i>PINK1</i> type of young-onset Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.ricciardi.2014.1561">Ricciardi et al 2014</a>]. Thus, in addition to parkinsonism, individuals with <i>PINK1</i> type of young-onset Parkinson disease may be prone to psychiatric involvement. Abnormal behavior and/or psychiatric manifestations &#x02013; in particular, depression (17%) and anxiety (10%) (see <a href="http://www.mdsgene.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a>) &#x02013; may occur in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and may be the initial symptom. Other features include frontal dysfunction, hallucinations, and dementia [<a class="bk_pop" href="#pink1-pd.REF.kasten.2010a.670">Kasten et al 2010a</a>, <a class="bk_pop" href="#pink1-pd.REF.ricciardi.2014.1561">Ricciardi et al 2014</a>]. Autonomic features were reported for 14% of individuals (see <a href="http://www.mdsgene.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a>). Hyposmia was reported in 6% of 139 individuals. Diminished color discrimination may be present even prior to motor onset [<a class="bk_pop" href="#pink1-pd.REF.eggers.2010.1798">Eggers et al 2010</a>].</p><p>On average, the response to L-dopa is better than in <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.valente.2010">Valente &#x00026; Ferraris 2010</a>]; however, the incidence of L-dopa-induced dyskinesias may be greater in individuals with <i>PINK1</i>-associated young-onset Parkinson disease than in those with parkinsonism of different etiologies [<a class="bk_pop" href="#pink1-pd.REF.nishioka.2010.391">Nishioka et al 2010</a>].</p><p><b>Neuroimaging.</b> CT and MRI neuroimaging of individuals with <i>PINK1</i>-associated young-onset Parkinson disease is usually normal.</p><p>Imaging of dopamine function (using 123-I-FP-CIT, DaTSCAN) generally demonstrated relatively symmetric loss of radioligand uptake in the striatum, similar to the pattern seen in the <a href="/books/n/gene/jpd/">Parkin type of young-onset Parkinson disease</a> (but also <a href="/books/n/gene/lrrk2/"><i>LRRK2 </i>(Gly2019Ser) type of Parkinson disease</a> and <a href="/books/n/gene/parkinson-overview/"><i>SNCA</i> type of Parkinson disease</a>) [<a class="bk_pop" href="#pink1-pd.REF.mcneill.2013.e69190">McNeill et al 2013</a>].</p><p>Reduced presynaptic striatal uptake is also depicted by <sup>18</sup>F-dopa-PET studies in both <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> individuals and asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> relatives, who had 85% reduction and 20%-30% reduction in uptake, respectively [<a class="bk_pop" href="#pink1-pd.REF.khan.2002.849">Khan et al 2002</a>, <a class="bk_pop" href="#pink1-pd.REF.eggers.2010.1798">Eggers et al 2010</a>].</p><p>In another study PET imaging with a dopamine D2 receptor ligand 11C-raclopride in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant revealed that postsynaptic 11C-raclopride uptake was normal in the bilateral putamen [<a class="bk_pop" href="#pink1-pd.REF.yamashita.2008.662">Yamashita et al 2008</a>].</p><p>MR spectroscopy demonstrated raised myoinositol levels in the basal ganglia of the two individuals who were imaged, reflecting possible astroglial proliferation [<a class="bk_pop" href="#pink1-pd.REF.prestel.2008.643">Prestel et al 2008</a>]. <a class="bk_pop" href="#pink1-pd.REF.hilker.2012.e51308">Hilker et al [2012]</a> performed phosphorous ((31)P) and proton ((1)H) 3-T magnetic resonance spectroscopic imaging and found putaminal GPC, PCr, HEP, and &#x003b2;-ATP levels well above the 2SD range compared to controls, suggesting that the dopaminergic deficit in <a href="/books/n/gene/jpd/"><i>PINK1</i> type of young-onset Parkinson</a> disease relates to osmolyte dysregulation, while the delivery of high-energy phosphates is preserved.</p><p><b>Neuropathology.</b> Neuropathologic data in individuals with <i>PINK1</i> pathogenic variants are limited [<a class="bk_pop" href="#pink1-pd.REF.samaranch.2010.1128">Samaranch et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.poulopoulos.2012.831">Poulopoulos et al 2012</a>]. Brain autopsy data are available only for one individual who was a compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and a <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7) with onset of disease at age 31 years [<a class="bk_pop" href="#pink1-pd.REF.samaranch.2010.1128">Samaranch et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.poulopoulos.2012.831">Poulopoulos et al 2012</a>]. Pathology study revealed significant presence of Lewy bodies and neuronal loss in the substantia nigra pars compacta with sparing of the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> coeruleus, which would be atypical for <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease. The brain stem reticular formation and the nucleus basalis of Meynert were also affected. There were no tau- or TDP43-positive inclusions. In a Parkinson disease brain bank study, <a class="bk_pop" href="#pink1-pd.REF.gandhi.2006.1720">Gandhi et al [2006]</a> identified four individuals with Parkinson disease and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>PINK1</i> pathogenic variants who showed pathologic findings consistent with classic Parkinson disease with Lewy bodies distributed in the brain stem and cortical areas, and neuronal loss affecting the substantia nigra pars compacta and neurofibrillary tangles Stage I to V.</p><div id="pink1-pd.Heterozygotes"><h4>Heterozygotes</h4><p>Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> usually remain asymptomatic but may show subtle subclinical alterations (e.g., a latent nigrostriatal dopaminergic deficit on functional imaging, premotor-motor excitability changes detected by transcranial magnetic stimulation, reduced arm swing) [<a class="bk_pop" href="#pink1-pd.REF.n_rnberger.2015.386">N&#x000fc;rnberger et al 2015</a>, <a class="bk_pop" href="#pink1-pd.REF.weissbach.2017.275">Weissbach et al 2017</a>]. Hyposmia and diminished color discrimination may also be present in heterozygotes [<a class="bk_pop" href="#pink1-pd.REF.eggers.2010.1798">Eggers et al 2010</a>]. In asymptomatic heterozygotes, voxel-based morphometry revealed an increase of putaminal and pallidal gray matter volume, findings generally similar to those in the <a href="/books/n/gene/jpd/">Parkin type of young-onset Parkinson disease</a> [<a class="bk_pop" href="#pink1-pd.REF.binkofski.2007.842">Binkofski et al 2007</a>, <a class="bk_pop" href="#pink1-pd.REF.reetz.2010.402">Reetz et al 2010</a>].</p></div></div><div id="pink1-pd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No correlation between the type of variant and age at onset, clinical presentation, or disease progression has yet been observed.</p><p>Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> <i>PINK1</i> pathogenic variants and <a class="def" href="/books/n/gene/glossary/def-item/homoplasmic/">homoplasmic</a> for two mitochondrially encoded DNA (mtDNA) variants (<i>MT-ND5</i> and <i>MT-ND6</i>, encoding two subunits of complex I) had very early onset of symptoms [<a class="bk_pop" href="#pink1-pd.REF.piccoli.2008.596">Piccoli et al 2008</a>]. It is possible that the combination of pathogenic variants in both genes accelerated the disease onset.</p></div><div id="pink1-pd.Penetrance"><h3>Penetrance</h3><p>Penetrance is age dependent but appears to be complete in individuals who have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>PINK1</i> pathogenic variants.</p></div><div id="pink1-pd.Prevalence"><h3>Prevalence</h3><p>The prevalence is not known. Overall, <i>PINK1</i> pathogenic variants are a rare cause of early-onset parkinsonism [<a class="bk_pop" href="#pink1-pd.REF.marongiu.2008.565">Marongiu et al 2008</a>].</p><p>The proportion of men among individuals with <i>PINK1</i> type of young-onset Parkinson disease is 42%. The majority of families are of mixed ethnicity (32%) or white (33%); 18% are Asian. Most reported families originate from Italy (20%), Ireland (10%), or Spain (8%) (see <a href="http://www.mdsgene.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mdsgene.org</a>) [<a class="bk_pop" href="#pink1-pd.REF.kasten.2018.730">Kasten et al 2018</a>].</p></div></div><div id="pink1-pd.Genetically_Related_Allelic_Dis"><h2 id="_pink1-pd_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>A few reports suggest that <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>PINK1</i> pathogenic variants could result in <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> Parkinson disease or constitute a risk factor for Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.criscuolo.2006.1265">Criscuolo et al 2006</a>, <a class="bk_pop" href="#pink1-pd.REF.toft.2007.82">Toft et al 2007</a>, <a class="bk_pop" href="#pink1-pd.REF.kasten.2010b.952">Kasten et al 2010b</a>]. In a systematic review of 62 individuals with Parkinson disease with a heterozygous <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the average age of onset was 42.3&#x000b1;15.7 years (10 years later than in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants [<a class="bk_pop" href="#pink1-pd.REF.kasten.2010b.952">Kasten et al 2010b</a>]). <a class="bk_pop" href="#pink1-pd.REF.marongiu.2008.565">Marongiu et al [2008]</a> determined the occurrence of <i>PINK1</i> heterozygous rare variants in more than 1,100 individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Parkinson disease of all onset ages and in 400 controls. Their meta-analysis indicated that in <i>PINK1</i> heterozygotes, the risk for Parkinson disease is only slightly increased, with a nonsignificant odds ratio of 1.62. These findings suggest that <i>PINK1</i> heterozygous pathogenic variants play only a minor susceptibility role in the context of a <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a> model of Parkinson disease. This is in contrast to a recent report by <a class="bk_pop" href="#pink1-pd.REF.puschmann.2016">Puschmann et al [2016]</a>, who found a markedly increased risk for Parkinson disease (odds ratio = 2.92, P = 0.032) in individuals heterozygous for the <i>PINK1</i> pathogenic variant <a class="figpopup" href="/books/NBK26472/table/pink1-pd.T.pink1_pathogenic_variants_dis/?report=objectonly" target="object" rid-figpopup="figpink1pdTpink1pathogenicvariantsdis" rid-ob="figobpink1pdTpink1pathogenicvariantsdis">p.Gly411Ser</a> when comparing 2,560 individuals with Parkinson disease and 2,145 controls in a genetic association study.</p></div><div id="pink1-pd.Differential_Diagnosis"><h2 id="_pink1-pd_Differential_Diagnosis_">Differential Diagnosis</h2><p>Clinically, <i>PINK1</i> type of young-onset Parkinson disease and <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease are difficult to differentiate (see <a href="/books/n/gene/parkinson-overview/">Parkinson Disease Overview</a>). More than 80% of individuals with Parkinson disease have no family history of the disorder. A monogenic cause of Parkinson disease can be identified in some individuals with a positive family history.</p><p><a href="/books/n/gene/jpd/">Parkin type of early-onset Parkinson disease</a>, caused by mutation of <i>PRKN</i> (formerly <i>PARK2</i>), is more common than <i>PINK1</i> type of young-onset Parkinson disease. The clinical findings in individuals with pathogenic variants in <i>PRKN</i> and <i>PINK1</i> are indistinguishable.</p><p>Another disorder in the differential diagnosis is the <i>PARK7</i>-type of young-onset Parkinson disease (OMIM <a href="http://www.omim.org/entry/606324" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606324</a>), which also presents as an early-onset disorder with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> generally similar to <i>PINK1</i> type of young-onset Parkinson disease.</p><p>For individuals with juvenile-onset Parkinson disease, especially those with prominent dystonia, dopa-responsive dystonia should be considered &#x02013; for example, <a href="/books/n/gene/drd/">GTP cyclohydrolase 1-deficient dopa-responsive dystonia</a>, caused by <i>GCH1</i> pathogenic variants.</p></div><div id="pink1-pd.Management"><h2 id="_pink1-pd_Management_">Management</h2><div id="pink1-pd.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>PINK1</i> type of young-onset Parkinson disease, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Assessment for presence/severity of atypical signs using the Unified Parkinson Disease Rating Scale [<a class="bk_pop" href="#pink1-pd.REF.goetz.2008.2129">Goetz et al 2008</a>]</div></li><li class="half_rhythm"><div>Evaluation of the degree of response to treatment and its potential complications</div></li><li class="half_rhythm"><div>Assessment for cognitive or behavioral problems</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="pink1-pd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>To date, the treatment of <i>PINK1</i> type of young-onset Parkinson disease is not different from that of <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease and no specific guidelines or recommendations have been developed. For general treatment guidelines for Parkinson disease see <a class="bk_pop" href="#pink1-pd.REF.ferreira.2013.5">Ferreira et al [2013]</a>.</p><p>Individuals with <i>PINK1</i> type of young-onset Parkinson disease have a mild form of Parkinson disease that responds well to levodopa (L-dopa) and to other dopaminergic agonists.</p><ul><li class="half_rhythm"><div>Response is usually significant and is sustained for low doses of L-dopa even after long disease duration. The response may be even better in individuals with <i>PINK1</i> type of young-onset Parkinson disease than in individuals with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.valente.2010">Valente &#x00026; Ferraris 2010</a>].</div></li><li class="half_rhythm"><div>The major problem is the early occurrence of severe L-dopa-induced dyskinesias (abnormal involuntary movements) and fluctuations. Fluctuations can be reduced by a combination of dopamine therapies (e.g., dopamine agonists), adding COMT inhibitors, and keeping the doses of L-dopa as low as possible.</div></li><li class="half_rhythm"><div>The successful use of deep brain stimulation in individuals with <i>PINK1</i> type of young-onset Parkinson disease has been described [<a class="bk_pop" href="#pink1-pd.REF.moro.2008.1186">Moro et al 2008</a>, <a class="bk_pop" href="#pink1-pd.REF.johansen.2011.201">Johansen et al 2011</a>].</div></li></ul></div><div id="pink1-pd.Prevention_of_Secondary_Complic"><h3>Prevention of Secondary Complications</h3><p>To reduce or delay side effects, L-dopa dosage should not exceed the level required for satisfactory clinical response. If not contraindicated, dopamine agonists should be employed to possibly delay the onset of motor fluctuations, as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals often require several decades of treatment.</p></div><div id="pink1-pd.Surveillance"><h3>Surveillance</h3><p>Neurologic follow up every three to 12 months to modify treatment as needed is appropriate. No formal guidelines for surveillance have been formulated.</p></div><div id="pink1-pd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Neuroleptic treatment may exacerbate parkinsonism.</p></div><div id="pink1-pd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Owing to the absence of preventive treatment or measures, presymptomatic genetic diagnosis is not medically justified.</p><p>See <a href="#pink1-pd.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pink1-pd.Pregnancy_Management"><h3>Pregnancy Management</h3><p>There are no reports specifically addressing pregnancy management in women with <i>PINK1</i> type of young-onset Parkinson disease. However, in general, pregnancy may either exacerbate or improve symptoms of Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.shulman.2000.132">Shulman et al 2000</a>, <a class="bk_pop" href="#pink1-pd.REF.scott.2005.1078">Scott &#x00026; Chowdhury 2005</a>]. L-dopa crosses the placenta and (theoretically) may have an adverse effect on fetal development, as some animal models have shown that high doses of L-dopa administered during pregnancy may induce stillbirth and birth defects including skeletal malformations [<a class="bk_pop" href="#pink1-pd.REF.scott.2005.1078">Scott &#x00026; Chowdhury 2005</a>]. However, based on more than 30 individuals recorded in the literature, L-dopa treatment during human pregnancy has not resulted in adverse fetal outcome [<a class="bk_pop" href="#pink1-pd.REF.scott.2005.1078">Scott &#x00026; Chowdhury 2005</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="pink1-pd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="pink1-pd.Genetic_Counseling"><h2 id="_pink1-pd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pink1-pd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>PINK1</i> type of young-onset Parkinson disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="pink1-pd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>The risk to heterozygotes of developing symptoms is not yet determined; however, several individuals with parkinsonism who have a single <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported (see <a href="#pink1-pd.Genetically_Related_Allelic_Dis">Genetically Related Disorders</a>) [<a class="bk_pop" href="#pink1-pd.REF.ishiharapaul.2008.896">Ishihara-Paul et al 2008</a>, <a class="bk_pop" href="#pink1-pd.REF.lesage.2009.r48">Lesage &#x00026; Brice 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.tan.2009.1551">Tan et al 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.kasten.2010a.670">Kasten et al 2010a</a>, <a class="bk_pop" href="#pink1-pd.REF.zhang.2011.490">Zhang et al 2011</a>]</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>The risk to heterozygotes of developing symptoms is not yet determined, although several individuals with parkinsonism who have a single <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported (see <a href="#pink1-pd.Genetically_Related_Allelic_Dis">Genetically Related Disorders</a>) [<a class="bk_pop" href="#pink1-pd.REF.ishiharapaul.2008.896">Ishihara-Paul et al 2008</a>, <a class="bk_pop" href="#pink1-pd.REF.lesage.2009.r48">Lesage &#x00026; Brice 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.tan.2009.1551">Tan et al 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.biswas.2010.167">Biswas et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.kasten.2010a.670">Kasten et al 2010a</a>, <a class="bk_pop" href="#pink1-pd.REF.keyser.2010.125">Keyser et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.zhang.2011.490">Zhang et al 2011</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with <i>PINK1</i> type of young-onset Parkinson disease are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PINK1</i>.</div></li><li class="half_rhythm"><div>The risk to offspring of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> depends on the frequency of heterozygotes in the general population, which is unknown; however, based on current knowledge, the proportion of heterozygotes is probably less than 1%, generating a risk of less than 0.25% to offspring of being affected. As with other <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorders, the risk is higher when the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and his/her reproductive partner are related.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="pink1-pd.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>PINK1</i> pathogenic variants in the family.</p></div><div id="pink1-pd.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pink1-pd.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>PINK1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="pink1-pd.Resources"><h2 id="_pink1-pd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Parkinson Disease Association (APDA)</b></div><div>135 Parkinson Avenue</div><div>Staten Island NY 10305</div><div><b>Phone:</b> 800-223-2732 (toll-free); 718-981-8001</div><div><b>Fax:</b> 718-981-4399</div><div><b>Email:</b> apda@apdaparkinson.org</div><div><a href="http://www.apdaparkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.apdaparkinson.org</a></div></li><li class="half_rhythm"><div><b>Michael J. Fox Foundation for Parkinson's Research</b></div><div>Church Street Station</div><div>PO Box 780</div><div>New York NY 10008-0780</div><div><b>Phone:</b> 800-708-7644 (toll-free)</div><div><b>Email:</b> info@michaeljfox.org</div><div><a href="http://www.michaeljfox.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.michaeljfox.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=parkinsondisease" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parkinson disease</a></div></li><li class="half_rhythm"><div><b>Parkinson's Foundation</b></div><div>200 SE 1st Street</div><div>Suite 800</div><div>Miami FL 33131</div><div><b>Phone:</b> 800-4PD-INFO (473-4636)</div><div><b>Email:</b> contact@parkinson.org</div><div><a href="http://www.parkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.parkinson.org</a></div></li></ul></div><div id="pink1-pd.Molecular_Genetics"><h2 id="_pink1-pd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pink1-pd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>PINK1 Type of Young-Onset Parkinson Disease : Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26472/table/pink1-pd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pink1-pd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pink1-pd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pink1-pd.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">PARK6</td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/65018" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PINK1</i></a></td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=65018" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p36<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BXM7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase PINK1, mitochondrial</a></td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=2&#x00026;geneId=EG65018" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PD mutation database (PINK1)</a><br /><a href="http://www.LOVD.nl/PINK1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parkinson's disease Mutation Database (PINK1)</a><br /><a href="http://www.mdsgene.org/d/2/g/5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Movement Disorder Society Genetic mutation database (PINK1)</a></td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PINK1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PINK1</a></td><td headers="hd_b_pink1-pd.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PINK1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PINK1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pink1-pd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pink1-pd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for PINK1 Type of Young-Onset Parkinson Disease (<a href="/omim/605909,608309" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26472/table/pink1-pd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pink1-pd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605909" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605909</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608309" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608309</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTEN-INDUCED PUTATIVE KINASE 1; PINK1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>PINK1</i> contains eight exons (<a href="/nuccore/NM_032409.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_032409.2</a>) spanning about 18 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK26472/#pink1-pd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The most common <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, p.Gln456Ter, was identified in 12 of 139 (9%) reported individuals. Overall, three quarters of individuals had <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> pathogenic variants that were each identified in no more than five individuals. Changes have been identified in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a>, compound-<a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, and heterozygous state. Variants include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants and small insertions. Rarely, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>, multiexon [<a class="bk_pop" href="#pink1-pd.REF.li.2005.1955">Li et al 2005</a>, <a class="bk_pop" href="#pink1-pd.REF.cazeneuve.2009.265">Cazeneuve et al 2009</a>], and whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions [<a class="bk_pop" href="#pink1-pd.REF.marongiu.2007.98">Marongiu et al 2007</a>] have been described.</p><div id="pink1-pd.T.pink1_pathogenic_variants_dis" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>PINK1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26472/table/pink1-pd.T.pink1_pathogenic_variants_dis/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pink1-pd.T.pink1_pathogenic_variants_dis_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1231G&#x0003e;A</td><td headers="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly411Ser</td><td headers="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_032409.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_032409<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_115785.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_115785<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1366C&#x0003e;T</td><td headers="hd_h_pink1-pd.T.pink1_pathogenic_variants_dis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln456Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene encodes a 581-amino-acid serine/threonine kinase, PTEN-induced putative kinase 1 (<a href="/protein/NP_115785.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_115785.1</a>). The PINK1 kinase is located in the mitochondria spanning the outer mitochondrial membrane with the C-terminal kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> facing the cytoplasm and the N-terminal end inside the mitochondria. PINK1 presumably exerts its neuroprotective effect by phosphorylating specific mitochondrial proteins and, in turn, modulating their functions [<a class="bk_pop" href="#pink1-pd.REF.sim.2006.3251">Sim et al 2006</a>]. PINK1 thereby promotes elimination of dysfunctional mitochondria by autophagy. Notably, PINK1 and parkin (see <a href="/books/n/gene/parkinson-overview/">Parkinson Disease Overview</a>) have been mapped to a shared pathway, with PINK1 acting upstream of parkin, where it can initiate the <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> of parkin to mitochondria [<a class="bk_pop" href="#pink1-pd.REF.hoepken.2007.401">Hoepken et al 2007</a>, <a class="bk_pop" href="#pink1-pd.REF.gandhi.2009.627">Gandhi et al 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.narendra.2010.e1000298">Narendra et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.vivesbauza.2010.378">Vives-Bauza et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.rakovic.2013.2223">Rakovic et al 2013</a>, <a class="bk_pop" href="#pink1-pd.REF.kitagishi.2017.3">Kitagishi et al 2017</a>].</p><p><b>Abnormal</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most of the known pathogenic variants are localized within the serine/threonine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>PINK1</i> as expected [<a class="bk_pop" href="#pink1-pd.REF.valente.2004.1158">Valente et al 2004</a>]. <i>PINK1</i> pathogenic variants or PINK1 silencing result in reduced mtDNA levels, defective ATP production, impaired mitochondrial calcium handling, and increased free radical generation. This in turn results in a reduction of mitochondrial membrane potential and an increased susceptibility to apoptosis in neuronal cells, animal models, and patient-derived fibroblasts [<a class="bk_pop" href="#pink1-pd.REF.valente.2004.1158">Valente et al 2004</a>, <a class="bk_pop" href="#pink1-pd.REF.gegg.2009.e4756">Gegg et al 2009</a>, <a class="bk_pop" href="#pink1-pd.REF.abramov.2011.e25622">Abramov et al 2011</a>].</p><p>Overexpression of the parkin protein can rescue the effects of a <i>PINK1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>Drosophila</i> and mammalian cells. Studies in fibroblasts from human individuals with Parkinson disease revealed impaired ubiquitination of mitofusins and confirmed the link between the PINK1 and parkin pathways [<a class="bk_pop" href="#pink1-pd.REF.rakovic.2010.3124">Rakovic et al 2010</a>, <a class="bk_pop" href="#pink1-pd.REF.rakovic.2011.e16746">Rakovic et al 2011</a>, <a class="bk_pop" href="#pink1-pd.REF.seibler.2011.5970">Seibler et al 2011</a>, <a class="bk_pop" href="#pink1-pd.REF.rakovic.2013.2223">Rakovic et al 2013</a>, <a class="bk_pop" href="#pink1-pd.REF.koyano.2014.162">Koyano et al 2014</a>]. A link with LRRK2 [<a class="bk_pop" href="#pink1-pd.REF.azkona.2018.506">Azkona et al 2018</a>] and alpha-synuclein levels [<a class="bk_pop" href="#pink1-pd.REF.chung.2016.664">Chung et al 2016</a>] has also been demonstrated. PINK1-patient-specific induced pluripotent stem cell-derived midbrain dopamine neurons exhibit mitochondrial dysfunction with increased susceptibility to mitochondrial toxins [<a class="bk_pop" href="#pink1-pd.REF.chung.2016.664">Chung et al 2016</a>]. Animal studies of <i>Pink1</i> knockout mice showed defects in mitochondrial depolarization and synaptic transmission that were rescued by phosphomimetic NdufA10 in knockout mouse cells and in pink(B9)-null mutated <i>Drosophila</i> [<a class="bk_pop" href="#pink1-pd.REF.morais.2014.203">Morais et al 2014</a>]. Complex I deficits and adenosine triphosphate synthesis were also rescued in cells derived from individuals with <i>PINK1</i> type of young-onset Parkinson disease [<a class="bk_pop" href="#pink1-pd.REF.morais.2014.203">Morais et al 2014</a>]. Heterozygous <i>Pink1</i> knockout (Pink(+/-)) mice show subtle alterations of dopamine-dependent striatal synaptic plasticity [<a class="bk_pop" href="#pink1-pd.REF.madeo.2014.41">Madeo et al 2014</a>]. While chronic exposure to low doses of rotenone was not sufficient to alter mitochondrial integrity and ATP production in this model, the rotenone led to profound impairment in expression of long-term plasticity at corticostriatal synapses, suggesting that disruption of synaptic plasticity may represent an early feature of a pre-manifesting state of the disease [<a class="bk_pop" href="#pink1-pd.REF.martella.2016.21">Martella et al 2016</a>]. Findings of possible translational and treatment relevance include the role of vitamin K<sub>2</sub> as a mitochondrial electron carrier rescuing PINK1 deficiency [<a class="bk_pop" href="#pink1-pd.REF.vos.2012.1306">Vos et al 2012</a>] and the observation that cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency [<a class="bk_pop" href="#pink1-pd.REF.vos.2017.695">Vos et al 2017</a>].</p></div><div id="pink1-pd.References"><h2 id="_pink1-pd_References_">References</h2><div id="pink1-pd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.abramov.2011.e25622">Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C, Schapira AH. Bioenergetic consequences of PINK1 mutations in Parkinson disease. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e25622.</span> [<a href="/pmc/articles/PMC3197155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3197155</span></a>] [<a href="/pubmed/22043288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22043288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.azkona.2018.506">Azkona G, L&#x000f3;pez de Maturana R, Del Rio P, Sousa A, Vazquez N, Zubiarrain A, Jimenez-Blasco D, Bola&#x000f1;os JP, Morales B, Auburger G, Arbelo JM, S&#x000e1;nchez-Pernaute R. LRRK2 expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1. <span><span class="ref-journal">Mol Neurobiol. </span>2018;<span class="ref-vol">55</span>:506–16.</span> [<a href="/pmc/articles/PMC5808058/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5808058</span></a>] [<a href="/pubmed/27975167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27975167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.berardelli.2013.16">Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. <span><span class="ref-journal">Eur J Neurol. </span>2013;<span class="ref-vol">20</span>:16–34.</span> [<a href="/pubmed/23279440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23279440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.binkofski.2007.842">Binkofski F, Reetz K, Gaser C, Hilker R, Hagenah J, Hedrich K, van Eimeren T, Thiel A, B&#x000fc;chel C, Pramstaller PP, Siebner HR, Klein C. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">69</span>:842–50.</span> [<a href="/pubmed/17724286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17724286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.biswas.2010.167">Biswas A, Sadhukhan T, Majumder S, Misra AK, Das SK, Ray K, Ray J, et al.  Evaluation of PINK1 variants in Indian Parkinson's disease patients. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2010;<span class="ref-vol">16</span>:167–71.</span> [<a href="/pubmed/19889566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19889566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.bonifati.2005.87">Bonifati V, Roh&#x000e9; CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, Tavella A, Marconi R, Nicholl DJ, Chien HF, Fincati E, Abbruzzese G, Marini P, De Gaetano A, Horstink MW, Maat-Kievit JA, Sampaio C, Antonini A, Stocchi F, Montagna P, Toni V, Guidi M, Dalla Libera A, Tinazzi M, De Pandis F, Fabbrini G, Goldwurm S, de Klein A, Barbosa E, Lopiano L, Martignoni E, Lamberti P, Vanacore N, Meco G, Oostra BA, et al.  Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:87–95.</span> [<a href="/pubmed/16009891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16009891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.cazeneuve.2009.265">Cazeneuve C, S&#x000e2;n C, Ibrahim SA, Mukhtar MM, Kheir MM, Leguern E, Brice A, Salih MA. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson's disease. <span><span class="ref-journal">Neurogenetics. </span>2009;<span class="ref-vol">10</span>:265–70.</span> [<a href="/pubmed/19214605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19214605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.chung.2016.664">Chung SY, Kishinevsky S, Mazzulli JR, Graziotto J, Mrejeru A, Mosharov EV, Puspita L, Valiulahi P, Sulzer D, Milner TA, Taldone T, Krainc D, Studer L, Shim JW. Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and &#x003b1;-synuclein accumulation. <span><span class="ref-journal">Stem Cell Reports. </span>2016;<span class="ref-vol">7</span>:664–77.</span> [<a href="/pmc/articles/PMC5063469/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5063469</span></a>] [<a href="/pubmed/27641647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27641647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.criscuolo.2006.1265">Criscuolo C, Volpe G, De Rosa A, Varrone A, Marongiu R, Mancini P, Salvatore E, Dallapiccola B, Filla A, Valente EM, De Michele G. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2006;<span class="ref-vol">21</span>:1265–7.</span> [<a href="/pubmed/16700027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16700027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.eggers.2010.1798">Eggers C, Schmidt A, Hagenah J, Br&#x000fc;ggemann N, Klein JC, Tadic V, Kertelge L, Kasten M, Binkofski F, Siebner H, Neumaier B, Fink GR, Hilker R, Klein C. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">74</span>:1798–805.</span> [<a href="/pubmed/20513816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20513816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.ferreira.2013.5">Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Sch&#x000fc;pbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <span><span class="ref-journal">Eur J Neurol. </span>2013;<span class="ref-vol">20</span>:5–15.</span> [<a href="/pubmed/23279439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23279439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.finckh.2016">Finckh U, Rie&#x000df; O. <a href="https://www.dgn.org/leitlinien/3219-030-010-idiopathisches-parkinson-syndrom" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">S3 guideline for idiopathic Parkinson syndrome</a> [in German]. Deuschl G, Oertel W, Reichmann H, eds. Deutsche Gesellschaft f&#x000fc;r Neurologie. 2016.</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.gandhi.2006.1720">Gandhi S, Muqit MM, Stanyer L, Healy DG, Abou-Sleiman PM, Hargreaves I, Heales S, Ganguly M, Parsons L, Lees AJ, Latchman DS, Holton JL, Wood NW, Revesz T. PINK1 protein in normal human brain and Parkinson's disease. <span><span class="ref-journal">Brain. </span>2006;<span class="ref-vol">129</span>:1720–31.</span> [<a href="/pubmed/16702191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16702191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.gandhi.2009.627">Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov AY. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. <span><span class="ref-journal">Mol Cell. </span>2009;<span class="ref-vol">33</span>:627–38.</span> [<a href="/pmc/articles/PMC2724101/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2724101</span></a>] [<a href="/pubmed/19285945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19285945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.gegg.2009.e4756">Gegg ME, Cooper JM, Schapira AH, Taanman JW. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. <span><span class="ref-journal">PLoS One. </span>2009;<span class="ref-vol">4</span>:e4756.</span> [<a href="/pmc/articles/PMC2649444/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2649444</span></a>] [<a href="/pubmed/19270741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19270741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.goetz.2008.2129">Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, et al.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <span><span class="ref-journal">Mov Disord. </span>2008;<span class="ref-vol">23</span>:2129–70.</span> [<a href="/pubmed/19025984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19025984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.hilker.2012.e51308">Hilker R, Pilatus U, Eggers C, Hagenah J, Roggendorf J, Baudrexel S, Klein JC, Neumaier B, Fink GR, Steinmetz H, Klein C, Hattingen E. The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations. <span><span class="ref-journal">PLoS One. </span>2012;<span class="ref-vol">7</span>:e51308.</span> [<a href="/pmc/articles/PMC3519591/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3519591</span></a>] [<a href="/pubmed/23251494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23251494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.hoepken.2007.401">Hoepken HH, Gispert S, Morales B, Wingerter O, Del Turco D, M&#x000fc;lsch A, Nussbaum RL, M&#x000fc;ller K, Dr&#x000f6;se S, Brandt U, Deller T, Wirth B, Kudin AP, Kunz WS, Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. <span><span class="ref-journal">Neurobiol Dis. </span>2007;<span class="ref-vol">25</span>:401–11.</span> [<a href="/pubmed/17141510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17141510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.ishiharapaul.2008.896">Ishihara-Paul L, Hulihan MM, Kachergus J, Upmanyu R, Warren L, Amouri R, Elango R, Prinjha RK, Soto A, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ. PINK1 mutations and parkinsonism. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">71</span>:896–902.</span> [<a href="/pmc/articles/PMC2676945/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2676945</span></a>] [<a href="/pubmed/18685134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18685134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.johansen.2011.201">Johansen KK, J&#x000f8;rgensen JV, White LR, Farrer MJ, Aasly JO. Parkinson-related genetics in patients treated with deep brain stimulation. <span><span class="ref-journal">Acta Neurol Scand. </span>2011;<span class="ref-vol">123</span>:201–6.</span> [<a href="/pubmed/20545633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20545633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.kasten.2018.730">Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, Balck A, Domingo A, Vulinovic F, Dulovic M, Zorn I, Madoev H, Zehnle H, Lembeck CM, Schawe L, Reginold J, Huang J, K&#x000f6;nig IR, Bertram L, Marras C, Lohmann K, Lill CM, Klein C. Genotype-phenotype relations for the Parkinson's disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review. <span><span class="ref-journal">Mov Disord. </span>2018;<span class="ref-vol">33</span>:730–41.</span> [<a href="/pubmed/29644727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29644727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.kasten.2010a.670">Kasten M, Kertelge L, Br&#x000fc;ggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens MI, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C. Nonmotor symptoms in genetic Parkinson disease. <span><span class="ref-journal">Arch Neurol. </span>2010a;<span class="ref-vol">67</span>:670–6.</span> [<a href="/pubmed/20558386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.kasten.2010b.952">Kasten M, Weichert C, Lohmann K, Klein C. Clinical and demographic characteristics of PINK1 mutation carriers &#x02013; a meta-analysis. <span><span class="ref-journal">Mov Disord. </span>2010b;<span class="ref-vol">25</span>:952–4.</span> [<a href="/pubmed/20461815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20461815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.keyser.2010.125">Keyser RJ, Lesage S, Brice A, Carr J, Bardien S. Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2010;<span class="ref-vol">398</span>:125–9.</span> [<a href="/pubmed/20558144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.khan.2002.849">Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">52</span>:849–53.</span> [<a href="/pubmed/12447943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12447943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.kitagishi.2017.3">Kitagishi Y, Nakano N, Ogino M, Ichimura M, Minami A, Matsuda S. PINK1 signaling in mitochondrial homeostasis and in aging &#x02013; Review. <span><span class="ref-journal">Int J Mol Med. </span>2017;<span class="ref-vol">39</span>:3–8.</span> [<a href="/pubmed/27959386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27959386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.koyano.2014.162">Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe JF, Saeki Y, Tanaka K, Matsuda N. Ubiquitin is phosphorylated by PINK1 to activate parkin. <span><span class="ref-journal">Nature. </span>2014;<span class="ref-vol">510</span>:162–6.</span> [<a href="/pubmed/24784582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24784582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.lesage.2009.r48">Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:R48–R59.</span> [<a href="/pubmed/19297401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19297401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.li.2005.1955">Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H, Toda T, Mizuno Y, Hattori N. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:1955–7.</span> [<a href="/pubmed/15955953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15955953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.madeo.2014.41">Madeo G, Schirinzi T, Martella G, Latagliata EC, Puglisi F, Shen J, Valente EM, Federici M, Mercuri NB, Puglisi-Allegra S, Bonsi P, Pisani A. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:41–53.</span> [<a href="/pmc/articles/PMC4022284/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4022284</span></a>] [<a href="/pubmed/24167038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24167038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.marongiu.2007.98">Marongiu R, Brancati F, Antonini A, Ialongo T, Ceccarini C, Scarciolla O, Capalbo A, Benti R, Pezzoli G, Dallapiccola B, Goldwurm S, Valente EM. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:98.</span> [<a href="/pubmed/17154281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17154281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.marongiu.2008.565">Marongiu R, Ferraris A, Ialongo T, Michiorri S, Soleti F, Ferrari F, Elia AE, Ghezzi D, Albanese A, Altavista MC, Antonini A, Barone P, Brusa L, Cortelli P, Martinelli P, Pellecchia MT, Pezzoli G, Scaglione C, Stanzione P, Tinazzi M, Zecchinelli A, Zeviani M, Cassetta E, Garavaglia B, Dallapiccola B, Bentivoglio AR, Valente EM, et al.  PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:565.</span> [<a href="/pubmed/18330912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18330912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.martella.2016.21">Martella G, Madeo G, Maltese M, Vanni V, Puglisi F, Ferraro E, Schirinzi T, Valente EM, Bonanni L, Shen J, Mandolesi G, Mercuri NB, Bonsi P, Pisani A. Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. <span><span class="ref-journal">Neurobiol Dis. </span>2016;<span class="ref-vol">91</span>:21–36.</span> [<a href="/pubmed/26916954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26916954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.mcneill.2013.e69190">McNeill A, Wu RM, Tzen KY, Aguiar PC, Arbelo JM, Barone P, Bhatia K, Barsottini O, Bonifati V, Bostantjopoulou S, Bressan R, Cossu G, Cortelli P, Felicio A, Ferraz HB, Herrera J, Houlden H, Hoexter M, Isla C, Lees A, Lorenzo-Betancor O, Mencacci NE, Pastor P, Pappata S, Pellecchia MT, Silveria-Moriyama L, Varrone A, Foltynie T, Schapira AH. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e69190.</span> [<a href="/pmc/articles/PMC3720622/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3720622</span></a>] [<a href="/pubmed/23935950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23935950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.morais.2014.203">Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, Aerts L, Overbergh L, Gr&#x000fc;newald A, Seibler P, Klein C, Gevaert K, Verstreken P, De Strooper B. PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. <span><span class="ref-journal">Science. </span>2014;<span class="ref-vol">344</span>:203–7.</span> [<a href="/pubmed/24652937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24652937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.moro.2008.1186">Moro E, Volkmann J, K&#x000f6;nig IR, Winkler S, Hiller A, Hassin-Baer S, Herzog J, Schnitzler A, Lohmann K, Pinsker MO, Voges J, Djarmatic A, Seibler P, Lozano AM, Rogaeva E, Lang AE, Deuschl G, Klein C. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1186–91.</span> [<a href="/pubmed/18378882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18378882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.narendra.2010.e1000298">Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. <span><span class="ref-journal">PLoS Biol. </span>2010;<span class="ref-vol">8</span>:e1000298.</span> [<a href="/pmc/articles/PMC2811155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2811155</span></a>] [<a href="/pubmed/20126261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20126261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.nishioka.2010.391">Nishioka K, Kefi M, Jasinska-Myga B, Wider C, Vilarino-Guell C, Ross OA, Heckman MG, Middleton LT, Ishihara-Paul L, Gibson RA, Amouri R, Yahmed SB, Sassi SB, Zouari M, Euch GE, Farrer MJ, Hentati F. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson disease. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2010;<span class="ref-vol">81</span>:391–5.</span> [<a href="/pubmed/19726410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19726410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.n_rnberger.2015.386">N&#x000fc;rnberger L, Klein C, Baudrexel S, Roggendorf J, Hildner M, Chen S, Kang JS, Hilker R, Hagenah J. Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers. <span><span class="ref-journal">Mov Disord. </span>2015;<span class="ref-vol">30</span>:386–92.</span> [<a href="/pubmed/25545816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25545816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.piccoli.2008.596">Piccoli C, Ripoli M, Quarato G, Scrima R, D'Aprile A, Boffoli D, Margaglione M, Criscuolo C, De Michele G, Sardanelli A, Papa S, Capitanio N. Coexistence of mutations in PINK1 and mitochondrial DNA in early onset parkinsonism. <span><span class="ref-journal">J Med Genet. </span>2008;<span class="ref-vol">45</span>:596–602.</span> [<a href="/pubmed/18524835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18524835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.poulopoulos.2012.831">Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. <span><span class="ref-journal">Mov Disord. </span>2012;<span class="ref-vol">27</span>:831–42.</span> [<a href="/pmc/articles/PMC3383342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3383342</span></a>] [<a href="/pubmed/22451330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22451330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.prestel.2008.643">Prestel J, Gempel K, Hauser TK, Schweitzer K, Prokisch H, Ahting U, Freudenstein D, Bueltmann E, Naegele T, Berg D, Klopstock T, Gasser T. Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. <span><span class="ref-journal">J Neurol. </span>2008;<span class="ref-vol">255</span>:643–8.</span> [<a href="/pubmed/18286320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18286320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.puschmann.2016">Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilari&#x000f1;o-G&#x000fc;ell C, Farrer MJ, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Springer W (2016) Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain140:98-1. [<a href="/pmc/articles/PMC5379862/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5379862</span></a>] [<a href="/pubmed/27807026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27807026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.rakovic.2011.e16746">Rakovic A, Gr&#x000fc;newald A, Kottwitz J, Br&#x000fc;ggemann N, Pramstaller PP, Lohmann K, Klein C. Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e16746.</span> [<a href="/pmc/articles/PMC3050809/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3050809</span></a>] [<a href="/pubmed/21408142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21408142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.rakovic.2010.3124">Rakovic A, Gr&#x000fc;newald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:3124–37.</span> [<a href="/pubmed/20508036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20508036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.rakovic.2013.2223">Rakovic A, Shurkewitsch K, Seibler P, Gr&#x000fc;newald A, Zanon A, Hagenah J, Krainc D, Klein C. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. <span><span class="ref-journal">J Biol Chem. </span>2013;<span class="ref-vol">288</span>:2223–37.</span> [<a href="/pmc/articles/PMC3554895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3554895</span></a>] [<a href="/pubmed/23212910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23212910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.reetz.2010.402">Reetz K, Tadic V, Kasten M, Br&#x000fc;ggemann N, Schmidt A, Hagenah J, Pramstaller PP, Ramirez A, Behrens MI, Siebner HR, Klein C, Binkofski F. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. <span><span class="ref-journal">Neurobiol Dis. </span>2010;<span class="ref-vol">39</span>:402–8.</span> [<a href="/pubmed/20483373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20483373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.ricciardi.2014.1561">Ricciardi L, Petrucci S, Guidubaldi A, Ialongo T, Serra L, Ferraris A, Span&#x000f2; B, Bozzali M, Valente EM, Bentivoglio AR. Phenotypic variability of PINK1 expression: 12 years' clinical follow-up of two Italian families. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1561–6.</span> [<a href="/pubmed/25164310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164310</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.samaranch.2010.1128">Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, Pastor MA, Marrero C, Isla C, Herrera-Henriquez J, Pastor P. PINK1-linked parkinsonism is associated with Lewy body pathology. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:1128–42.</span> [<a href="/pubmed/20356854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20356854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.scott.2005.1078">Scott M, Chowdhury M. Pregnancy in Parkinson's disease: unique case report and review of the literature. <span><span class="ref-journal">Mov Disord. </span>2005;<span class="ref-vol">20</span>:1078–9.</span> [<a href="/pubmed/16001415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16001415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.seibler.2011.5970">Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1induced pluripotent stem cells. <span><span class="ref-journal">J Neurosci. </span>2011;<span class="ref-vol">31</span>:5970–6.</span> [<a href="/pmc/articles/PMC3091622/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3091622</span></a>] [<a href="/pubmed/21508222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21508222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.shulman.2000.132">Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. <span><span class="ref-journal">Mov Disord. </span>2000;<span class="ref-vol">15</span>:132–5.</span> [<a href="/pubmed/10634252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10634252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.sim.2006.3251">Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:3251–62.</span> [<a href="/pubmed/17000703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17000703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.tan.2009.1551">Tan EK, Refai FS, Siddique M, Yap K, Ho P, Fook-Chong S, Zhao Y. Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:1551–7.</span> [<a href="/pubmed/19847793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19847793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.toft.2007.82">Toft M, Myhre R, Pielsticker L, White LR, Aasly JO, Farrer MJ. PINK1 mutation heterozygosity and the risk of Parkinson's disease. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2007;<span class="ref-vol">78</span>:82–4.</span> [<a href="/pmc/articles/PMC2117782/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2117782</span></a>] [<a href="/pubmed/17172567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17172567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.valente.2010">Valente E, Ferraris A. Pink1 (PARK6) and Parkinson&#x02019;s disease. In: Schapira A, Lang AE, Fahn S. Saunders, eds. <em>Movement Disorders 4. Blue Books of Neurology</em>. Philadelphia, PA: Elsevier; 2010:66-82.</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.valente.2004.1158">Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonz&#x000e1;lez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. <span><span class="ref-journal">Science. </span>2004;<span class="ref-vol">304</span>:1158–60.</span> [<a href="/pubmed/15087508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15087508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.vivesbauza.2010.378">Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magran&#x000e9; J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2010;<span class="ref-vol">107</span>:378–83.</span> [<a href="/pmc/articles/PMC2806779/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2806779</span></a>] [<a href="/pubmed/19966284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19966284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.vos.2012.1306">Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap O, De Strooper B, Meganathan R, Morais VA, Verstreken P. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. <span><span class="ref-journal">Science. </span>2012;2012;<span class="ref-vol">336</span>:1306–10.</span> [<a href="/pubmed/22582012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22582012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.vos.2017.695">Vos M, Geens A, B&#x000f6;hm C, Deaulmerie L, Swerts J, Rossi M, Craessaerts K, Leites EP, Seibler P, Rakovic A, Lohnau T, De Strooper B, Fendt SM, Morais VA, Klein C, Verstreken P. Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency. <span><span class="ref-journal">J Cell Biol. </span>2017;<span class="ref-vol">216</span>:695–708.</span> [<a href="/pmc/articles/PMC5346965/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5346965</span></a>] [<a href="/pubmed/28137779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28137779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.weissbach.2017.275">Weissbach A, B&#x000e4;umer T, Pramstaller PP, Br&#x000fc;ggemann N, Tadic V, Chen R, Klein C, M&#x000fc;nchau A. Abnormal premotor-motor interaction in heterozygous Parkin- and Pink1 mutation carriers. <span><span class="ref-journal">Clin Neurophysiol. </span>2017;<span class="ref-vol">128</span>:275–80.</span> [<a href="/pubmed/27843055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27843055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.yamashita.2008.662">Yamashita H, Kohriyama T, Ohshita T, Takahashi T, Hashikawa K, Hattori N, Fukuyama H, Matsumoto M. Case of a 30-year history of PARK6 --findings from functional imaging of the brain. <span><span class="ref-journal">Rinsho Shinkeigaku. </span>2008;<span class="ref-vol">48</span>:662–5.</span> [<a href="/pubmed/19048950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19048950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pink1-pd.REF.zhang.2011.490">Zhang X, Zhang H, Liao B, Guo J, Xia K, Tang B. Mutation analysis of PINK1 gene in patients with early-onset Parkinsonism. <span><span class="ref-journal">Zhong Nan Da Xue Xue Bao Yi Xue Ban. </span>2011;<span class="ref-vol">36</span>:490–7.</span> [<a href="/pubmed/21743139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21743139</span></a>]</div></li></ul></div></div><div id="pink1-pd.Chapter_Notes"><h2 id="_pink1-pd_Chapter_Notes_">Chapter Notes</h2><div id="pink1-pd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>24 May 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 September 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 September 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 March 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>1 December 2009 (ck) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK26472</span><span class="label">PMID: <a href="/pubmed/20301792" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301792</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pik3ca-overgrowth/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/inad/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK26472&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK26472/?report=reader">PubReader</a></li><li><a href="/books/NBK26472/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK26472" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK26472" style="display:none" title="Cite this Page"><div class="bk_tt">Schneider SA, Klein C. PINK1 Type of Young-Onset Parkinson Disease. 2010 Mar 16 [Updated 2018 May 24]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK26472/pdf/Bookshelf_NBK26472.pdf">PDF version of this page</a> (207K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pink1-pd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pink1-pd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pink1-pd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pink1-pd.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pink1-pd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pink1-pd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pink1-pd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pink1-pd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pink1-pd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pink1-pd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pink1-pd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=65018[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PINK1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1953598" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1953598" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1953598" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1953598" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301651" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Parkin Type of Early-Onset Parkinson Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Parkin Type of Early-Onset Parkinson Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brüggemann N, Klein C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301610" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y, Kish S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301681" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28796472" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">VPS35</i>-Related Parkinson Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">VPS35</i>-Related Parkinson Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Deutschländer A, Ross OA, Wszolek ZK. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28749637" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301792" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301792" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041a57dde089116960f9ae">PINK1 Type of Young-Onset Parkinson Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">PINK1 Type of Young-Onset Parkinson Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:26:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CE3E7E041196100000000038F0151&amp;ncbi_session=CE8CE3E7E041A561_0911SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK26472%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK26472&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK26472/&amp;ncbi_pagename=PINK1 Type of Young-Onset Parkinson Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CE3E7E041A561_0911SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>